Presentation by Dr Emma Wilmot & Nick Rycroft, Derby

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Fraser Gibb, Edinburgh​​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Jackie Elliott, Sheffield​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Nicola Taylor, Dietitian, Derby​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Emma Wilmot, Derby​, DTN-UK Chair

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Geraldine Gallen, DSN, London

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Peter Hammond, Harrogate​​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Mike Kendall, DTN-UK representative​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Emma Wilmot, Derby​, DTN-UK Chair

Part of the DTN-UK Flash Glucose Monitoring Education Programme

In this double-blind, randomized trial, 'abstract of published paper' assigned patients with type 2 diabetes and

albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor,

at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular

filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area